Overview
CA 125 is a high-molecular-weight glycoprotein that serves as a tumor marker, as described in the document. It measures the concentration of cancer antigen 125 in the blood and is expressed from the MUC16 gene. It is normally found on epithelial cells lining the ovary, peritoneum, and pleura. Its primary clinical significance lies in its association with epithelial ovarian carcinoma, where it remains the most widely used serum marker.
Although CA 125 is a valuable tool, the document emphasizes that it has limited sensitivity and specificity in early-stage disease. CA 125 can miss a significant proportion of early ovarian cancers and may also be elevated in many benign conditions. For this reason, CA 125 is not recommended as a screening test for the general population. Instead, it is most useful when baseline levels are measured at the time of first histopathological diagnosis and then followed over time to monitor disease progression, treatment response, and early detection of recurrence or metastasis.
Symptoms
It itself does not cause symptoms. Any symptoms present are related to the underlying condition responsible for the elevated or abnormal CA 125 levels.
In ovarian cancer, symptoms may include abdominal bloating, pelvic pain, early satiety, unexplained weight loss, fatigue, or menstrual irregularities. In advanced disease, symptoms may extend to breathlessness, ascites, or generalized weakness.
When CA 125 is elevated due to benign conditions, symptoms vary depending on the cause. These may include pelvic pain in endometriosis, abdominal discomfort in liver disease, or systemic symptoms such as fever or malaise in inflammatory or autoimmune disorders. Because symptoms are non-specific, CA 125 values must always be interpreted alongside clinical findings and other investigations.
Causes
Elevation of CA 125 occurs due to increased expression or release of the antigen from epithelial surfaces, as outlined in the document.
Malignant causes primarily include epithelial ovarian carcinoma. It may also be elevated in cancers of the uterus, cervix, breast, lung, colon, pancreas, liver, and other organs. Non-Hodgkin lymphoma has also been associated with increased levels.
Benign causes are common and include physiological states such as ovulation, menstruation, and pregnancy. Gynecological conditions such as endometriosis, pelvic inflammatory disease, benign ovarian cysts, and uterine fibroids can raise CA 125 levels. Autoimmune disorders, gastrointestinal inflammation, peritonitis, and liver conditions such as chronic hepatitis, cirrhosis, and ascites are additional causes. Cardiac, renal, and pulmonary conditions, including heart failure, pleural effusion, and recent surgery, may also contribute to elevated levels.
Risk Factors
The primary risk factor for elevated CA 125 is the presence of ovarian cancer, particularly epithelial ovarian carcinoma. Individuals with a family history of ovarian cancer or known genetic predisposition are at increased risk and may undergo CA 125 testing as part of risk assessment and monitoring.
Other risk factors include chronic liver disease, autoimmune disorders, inflammatory gastrointestinal conditions, gynecological disorders, and physiological hormonal changes. Pregnancy and menstruation are notable non-pathological risk factors for temporary elevation. Because it lacks cancer specificity, individuals without malignancy may still show increased levels, highlighting the importance of cautious interpretation.
Prevention
There is no direct method to prevent CA 125 elevation, as it reflects underlying disease processes rather than acting as a causative factor. Prevention focuses on appropriate clinical use and interpretation, as emphasized in the document.
Key preventive strategies include establishing baseline levels at the time of confirmed ovarian cancer diagnosis and using serial measurements rather than isolated values. Correlating CA 125 levels with imaging studies, clinical findings, and other laboratory results reduces the risk of misinterpretation.
